Abstract: Chiral amino compounds, methods of preparation and uses thereof. Tamiflu can be obtained from the said compounds. Multi-substituted chiral tetrahydropyrrolyl amine which can be used as intermediate compounds of medicament can also be produced by the said compounds.

Abstract: Chiral amino compounds, methods of preparation and uses thereof. Tamiflu can be obtained from the said compounds. Multi-substituted chiral tetrahydropyrrolyl amine which can be used as intermediate compounds of medicament can also be produced by the said compounds.

Abstract: Certain aspects of the invention relates to small molecule autophagy inhibitors of the formula (I), and their use for treatment and prevention of cancers and acute pancreatitis. As disclosed herein, a small molecule inhibitor of autophagy was been identified from an image-based screen in a known bioactive library. It was found that this autophagy inhibitor functions by promoting the degradation of type III PI3 kinase complex which is required for initiating autophagy. Medicinal chemistry studies led to small molecular autophagy inhibitors with improved potency and selectivity.

Abstract: Described herein are novel pyrimidine-pyridine compounds, methods of inhibiting methionine aminopeptidase and treating disorders (or symptoms thereof) associated with methionine aminopeptidase, wherein a compound of the invention is administered to a subject.

Abstract: This invention pertains to a class of autophagy inducing compounds that treat diseases caused by misfolded protein aggregates and a screening method for identifying these compounds.

Abstract: The present invention discloses the compounds of formula I or their pharmaceutically acceptable salts, which are useful as CCR5 antagonists. The preparation and use of the compounds of formula I, pharmaceutical composition containing the same are also disclosed. Furthermore, the present invention discloses an intermediate for the preparation of the compounds of formula I.

Abstract: A compound having the formula: ##STR1## wherein R.sub.1 and R.sub.2 independently is selected from the group consisting of H, C.sub.3 -C.sub.12 straight or branched alkyl, aryl or lower alkyl-substituted aryl; or R.sub.1 and R.sub.2 may be joined to form a 4-to 6-membered saturated or unsaturated ring or a 4-to 6-membered saturated or unsaturated lower alkyl-substituted ring; R.sub.3 is H, C.sub.1 -C.sub.12 straight or branched alkyl, NO.sub.2, NH.sub.2, N.sub.3, CN, halogen, CO.sub.2 R, OR, or SR wherein R is H or lower alkyl; R.sub.4 is H, C.sub.1 -C.sub.12 straight or branched alkyl, NO.sub.2, NH.sub.2, N.sub.3, CN, halogen, CO.sub.2 R, OR, or SR wherein R is H or lower alkyl; A is nothing or a C.sub.1 -C.sub.5 alkylene to form a ring; Z is 0, NH, S or --CH.dbd.CH--; and n is an integer of 1-3; or a pharmaceutically acceptable salt thereof. The compounds are useful in compositions and methods for treating psychiatric and neurological disorders.